Two-page plain-language consent with teach-back for every cancer trial and treatment
Replace 30-page consent forms with a short plain summary the patient explains back in their own words before signing, so consent means understanding.
Trial consent documents run to tens of pages at university reading level; comprehension studies show many participants cannot state the purpose of the study or that treatment is experimental. The proposal is a regulatory requirement that every consent process include a two-page plain-language summary (reading age 12, translated, with pictograms for risk) followed by a documented teach-back, with the long form as an appendix. The EU Clinical Trials Regulation already requires lay summaries of results; this extends the principle upstream.
- Patients lack understanding, navigation and agency · Most patients cannot understand their options, find trials, or push back, so decisions are made for them.
- Trials enrol too few, too slowly · Fewer than one in ten adults with cancer joins a trial. Trials close for lack of patients, not lack of ideas.
Pages like this
not linked directly; found by shared links- IdeaPatients are told which trials they qualify for at every treatment decision, in writing
Shares Patients lack understanding, navigation and agency, Trials enrol too few, too slowly.
- PersonSusan Love
Shares Patients lack understanding, navigation and agency, Trials enrol too few, too slowly.
- CompanyTempus AI
Shares Patients lack understanding, navigation and agency, Trials enrol too few, too slowly.